Biotest AG — AGM Information 2006

May 11, 2006

News Details

Corporate | 11 May 2006 16:03

Biotest AG: Stock option programme fails to achieve required majority

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest AG: Stock option programme fails to achieve required majority from preferred shareholders Dreieich/Frankfurt/Main, 11 May 2006. With 83.46% of shareholders present, the Annual General Meeting of Biotest AG, Dreieich, today approved by a large majority (94.64%) the creation of conditional capital amounting to € 0.98 million to secure subscription rights under a company stock option programme. At the subsequent meeting of preferred shareholders, however, with 30.53% of shareholders present, the agenda item failed to achieve the required three-quarters majority. Consequently, it is not possible to implement the Biotest Long-Term Incentive Plan as scheduled. The programme would have enabled more than 50 executives to participate in Biotest AG as preferred shareholders. Biotest intended to use the programme to create additional performance incentives and enhance its appeal as an employer. Following the rejection of the programme, a new scheme will be developed shortly. The other motions proposed by the management were adopted with very few dissenting votes. These included approving the authorisation to buy back own shares as well as their subsequent disposal or withdrawal. The dividend was raised from € 0.11 per ordinary share and preferred share to € 0.12 and € 0.18 respectively. The distribution amount rose as a result by 77% to € 1.56 million. About Biotest Biotest AG, Dreieich, Germany is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulines, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In addition, Biotest also researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are used, for example, in blood transfusions. Biotest has around 1,100 employees worldwide and its shares are listed in the Frankfurt Stock Exchange’s Prime Standard. Biotest AG: Dr. Michael Ramroth, Tel: +49 (0)6103 801-338 Fax: +49 (0)6103 801-347, e-mail: michael.ramroth@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de German Securities Code Number, ISIN ordinary shares: 522720, DE0005227201 German Securities Code Number, ISIN preferred shares: 522723, DE0005227235 Listed: Prime Standard/Official market Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart (c)DGAP 11.05.2006 ————————————————————————— Language: English Issuer: Biotest AG Landsteinerstr. 5 63303 Dreieich Deutschland Phone: +49 – 6103 / 801 – 0 Fax: +49 – 6103 / 801 – 150 email: mail@biotest.de WWW: www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 indices: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service —————————————————————————